SmithKline Beecham's Nicorette/Nicoderm CQ generate $345 mil. in sales in 1996.
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE NICORETTE/NICODERM CQ SALES TOTAL $345 MIL. IN 1996, pacing SmithKline Beecham OTC product sales to a 20% increase to [pound]1.4 bil., or $2.37 bil. ([pound]1=$1.70), SB reported Feb. 18. Nicorette smoking cessation gum was launched in the first quarter of 1996, Nicoderm CQ transdermal patches in the third quarter. Together, the products captured 87% of the U.S. market for smoking cessation products, the company said.